Потенційні механізми кардіоваскулярної кальцифікації у хворих на хронічну хворобу нирок

  • O. Susla Тернопільський національний медичний університет імені І. Я. Горбачевського МОЗ України https://orcid.org/0000-0002-1078-5898
  • O. Bushtynska Тернопільський національний медичний університет імені І. Я. Горбачевського МОЗ України
  • I. Yakubyshyna Тернопільський національний медичний університет імені І. Я. Горбачевського МОЗ України
  • L. Logoyda Тернопільський національний медичний університет імені І. Я. Горбачевського МОЗ України
  • K. Symko Тернопільський національний медичний університет імені І. Я. Горбачевського МОЗ України
  • I. Mysula Тернопільський національний медичний університет імені І. Я. Горбачевського МОЗ України
DOI: https://doi.org/10.31450/ukrjnd.4(76).2022.09
Ключові слова: хронічна хвороба нирок, кардіоваскулярна кальцифікація, частинки кальційпротеїну, везикули матриксу, гемодіаліз, ендотеліальна дисфункція.

Анотація

Узагальнення даних літератури дозволяють на сьогодні стверджувати про важливу потенційну роль частинок кальційпротеїну, везикул матриксу та деградації позаклітинного матриксу в механізмах кардіоваскулярної кальцифікації при хронічній хворобі нирок (ХХН). Дискутується залучення до цих процесів кінцевих продуктів глікування, інсулінорезистентності, мікроРНК, порушення метаболізму заліза, перевантаження рідиною та гемодіалізного лікування. Підкреслено, що зазначені потенційні механізми ектопічної кальцифікації, які активно досліджують, прямо чи опосередковано пов’язані з ушкодженням/дисфункцією ендотелію, розладами метаболізму в системі оксиду азоту. Зроблено висновок про доцільність проведення подальших ґрунтовних наукових досліджень, тісної співпраці фахівців клінічної та експериментальної нефрології з метою оптимізації програм ранньої діагностики кардіоваскулярної кальцифікації, впровадження нових ефективних терапевтичних стратегій та покращення прогнозу у хворих на ХХН.

Завантаження

Дані завантаження ще не доступні.

Посилання

Hou YC, Lu CL, Zheng CM, Chen RM, Lin YF, Liu WC, et al.Emerging role of vitamins D and K in modulating uremic vascular calcification: The aspect of passive calcification. Nutrients. 2019; 11(1):152. doi:10.3390/nu11010152.

Cozzolino M, Ciceri P, Galassi A, Mangano M, Carugo S, Capelli I, et al. The Key Role of Phosphate on Vascular Calcification. Toxins (Basel). 2019;11(4):213. doi:10.3390/toxins11040213.

Hénaut L, Mary A, Chillon JM, Kamel S, Massy ZA. The Impact of Uremic Toxins on Vascular Smooth Muscle Cell Function. Toxins (Basel). 2018;10(6):218. doi:10.3390/toxins10060218.     

Moradi H, Sica DA, Kalantar-Zadeh K.Cardiovascular burden associated with uremic toxins in patients with chronic kidney disease. Am J Nephrol. 2013;38(2):136-48.  doi:10.1159/000351758.

Schlieper G, Schurgers L, Brandenburg V, Reutelingsperger C, Floege J.Vascular calcification in chronic kidney disease: an update. Nephrol Dial Transplant. 2016;31(1):31-9. doi: 10.1093/ndt/gfv111.

Susla ОB, Gozhenko АI, Bergier J, Мysula ІR, Shved МI, Lykhodid OM.  Calcification of heart and vessels in chronic kidney disease: problems of etiology and pathogenesis. Fiziol. Zh. 2017;63(5):80-93. doi:10.15407/fz63.05.080.

Disthabanchong S, Srisuwarn P.Mechanisms of Vascular Calcification in Kidney Disease. Adv Chronic Kidney Dis. 2019;26(6):417-26. doi:10.1053/j.ackd.2019.08.014.

Herrmann M, Schäfer C, Heiss A, Gräber S, Kinkeldey A, Büscher A, et al. Clearance of fetuin-A--containing calciprotein particles is mediated by scavenger receptor-A. Circ Res. 2012;111(5):575-84.  doi:10.1161/CIRCRESAHA.111.261479.

Pasch A, Farese S, Gräber S, Wald J, Richtering W, Floege J, et al.Nanoparticle-based test measures overall propensity for calcification in serum. J Am Soc Nephrol. 2012;23(10):1744-52.  doi:10.1681/ASN.2012030240.

Aghagolzadeh P, Bachtler M, Bijarnia R, Jackson C, Smith ER, Odermatt A, et al. Calcification of vascular smooth muscle cells is induced by secondary calciprotein particles and enhanced by tumor necrosis factor-α. Atherosclerosis. 2016;251:404-14. doi:10.1016/j.atherosclerosis.2016.05.044.

Chen W, Anokhina V, Dieudonne G, Abramowitz MK, Kashyap R, Yan C, et al.Patients with advanced chronic kidney disease and vascular calcification have a large hydrodynamic radius of secondary calciprotein particles. Nephrol Dial Transplant. 2019;34(6):992-1000. doi:10.1093/ndt/gfy117.

Yamada S, Tokumoto M, Tsuruya K, Tatsumoto N, Noguchi H, Kitazono T, et al.Fetuin-A decrease induced by a low-protein diet enhances vascular calcification in uremic rats with hyperphosphatemia. Am J Physiol Renal Physiol. 2015;309(8):F744-54. doi:10.1152/ajprenal.00017.2015.                       

Pasch A, Block GA, Bachtler M, Smith ER, Jahnen-Dechent W, Arampatzis S, et al.Blood Calcification Propensity, Cardiovascular Events, and Survival in Patients Receiving Hemodialysis in the EVOLVE Trial. Clin J Am Soc Nephrol. 2017;12(2):315-322. doi:10.2215/CJN.04720416.

Ruderman I, Smith ER, Toussaint ND, Hewitson TD, Holt SG.Longitudinal changes in bone and mineral metabolism after cessation of cinacalcet in dialysis patients with secondary hyperparathyroidism. BMC Nephrol. 2018;19(1):113. doi:10.1186/s12882-018-0910-9.

Bakhshian Nik A, Hutcheson JD, Aikawa E.Extracellular Vesicles As Mediators of Cardiovascular Calcification. Front Cardiovasc Med. 2017;4:78. doi:10.3389/fcvm.2017.00078.

Zazzeroni L, Faggioli G, Pasquinelli G.Mechanisms of Arterial Calcification: The Role of Matrix Vesicles. Eur J Vasc Endovasc Surg. 2018;55(3):425-432.  doi:10.1016/j.ejvs.2017.12.009.

Leopold JA.Vascular calcification: Mechanisms of vascular smooth muscle cell calcification. Trends Cardiovasc Med. 2015;25(4):267-74. doi:10.1016/j.tcm.2014.10.021.

Viegas CSB, Santos L, Macedo AL, Matos AA, Silva AP, Neves PL, et al.Chronic kidney disease circulating calciprotein particles and extracellular vesicles promote vascular calcification: A role for GRP (Gla-rich protein). Arterioscler Thromb Vasc Biol. 2018;38:575-87. doi:10.1161/ATVBAHA.117.310578.

Ngai D, Lino M, Bendeck MP.Cell-Matrix Interactions and Matricrine Signaling in the Pathogenesis of Vascular Calcification. Front Cardiovasc Med. 2018;5:174. doi:10.3389/fcvm.2018.00174.

Sena BF, Figueiredo JL, Aikawa E.Cathepsin S As an Inhibitor of Cardiovascular Inflammation and Calcification in Chronic Kidney Disease. Front Cardiovasc Med. 2018;4:88. doi:10.3389/fcvm.2017.00088.

Prusskiy FO.Cardiovascular complications in hemodialysis patients: current approaches to prolong and improve quality of patients’ life. Ukr J Nephrol Dial. 2019;3(63):53-61. doi:10.31450/ukrjnd.3(63).2019.08.

Vila Cuenca M, Hordijk PL, Vervloet MG.Most exposed: the endothelium in chronic kidney disease. Nephrol Dial Transplant. 2020;35(9):1478-87. doi:10.1093/ndt/gfz055.

Kobayashi S.Cardiovascular Events in Hemodialysis Patients: Challenging against Vascular Calcification. Ann Vasc Dis. 2017;10(1):1-7. doi:10.3400/avd.ra.17-00006.

Kooman JP, Dekker MJ, Usvyat LA, Kotanko P, van der Sande FM, Schalkwijk CG,et al. Inflammation and premature aging in advanced chronic kidney disease. Am J Physiol Renal Physiol. 2017;313(4):F938-F950. doi:10.1152/ajprenal.00256.2017.

Belmokhtar K, Ortillon J, Jaisson S, Massy ZA, Boulagnon Rombi C, Doué M, et al.Receptor for advanced glycation end products: a key molecule in the genesis of chronic kidney disease vascular calcification and a potential modulator of sodium phosphate co-transporter PIT-1 expression. Nephrol Dial Transplant. 2019;34(12):2018-30. doi:10.1093/ndt/gfz012.

Fiorentino TV, Prioletta A, Zuo P, Folli F.Hyperglycemia-induced oxidative stress and its role in diabetes mellitus related cardiovascular diseases. Curr Pharm Des. 2013;19(32):5695-703.doi:10.2174/1381612811319320005.

Deluyker D, Evens L, Bito V. Advanced glycation end products (AGEs) and cardiovascular dysfunction: focus on high molecular weight AGEs. Amino Acids. 2017;49(9):1535-1541. doi: 10.1007/s00726-017-2464-8.

Brownlee M.The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54(6):1615-25. doi:10.2337/diabetes.54.6.1615.

LitovkinaZI.Kliniko-patohenetychni osoblyvosti remodelyuvannya sertsya ta yoho korektsiya u khvorykh na diabetychnu nefropatiyu, yaki likuyut’sya hemodializom [dysertatsiia]. Ternopil: Ministerstvo okhorony zdorov’ya Ukrayiny, Ternopil’s’kyy natsional’nyy medychnyy universytet imeni I. Ya. Horbachevs’koho MOZ Ukrayiny; 2021. 270 s. [In Ukrainian].

Kyyak YH, Kyyak HY, Barnett OY.Specifics of diabetic cardiomyopathy in the cases of concomitant cardiovascular disease: clinical and ultrastructural examinations. IEJ. 2016;5(77):33-8.doi: 10.22141/2224-0721.5.77.2016.78751.

Dedov II, Shestakova MV.Sakharnyy diabet: ostryye i khronicheskiye oslozhneniya. M.: OOO “Izdatel’stvo “MIA”;2012.480 s. [In Russian].

Yuan X, Zhang Z, Gong K, Zhao P, Qin J, Liu N.Inhibition of reactive oxygen species/extracellular signal-regulated kinases pathway by pioglitazone attenuates advanced glycation end products-induced proliferation of vascular smooth muscle cells in rats. Biol Pharm Bull. 2011;34(5):618-23.doi:10.1248/bpb.34.618.

Sakaguchi T, Yan SF, Yan SD, Belov D, Rong LL, Sousa M, et al. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest. 2003;111(7):959-72.doi:10.1172/JCI17115.

Wang Z, Jiang Y, Liu N, Ren L, Zhu Y, An Y, et al. Advanced glycation end-product Nε-carboxymethyl-Lysine accelerates progression of atherosclerotic calcification in diabetes. Atherosclerosis. 2012;221(2):387-96.doi:10.1016/j.atherosclerosis.2012.01.019.

Koike S, Yano S, Tanaka S, Sheikh AM, Nagai A, Sugimoto T.Advanced Glycation End-Products Induce Apoptosis of Vascular Smooth Muscle Cells: A Mechanism for Vascular Calcification. Int J Mol Sci. 2016;17(9):1567.doi:10.3390/ijms17091567.

Suga T, Iso T, Shimizu T, Tanaka T, Yamagishi S, Takeuchi M, et al.Activation of receptor for advanced glycation end products induces osteogenic differentiation of vascular smooth muscle cells. JAtheroscler Thromb.2011;18(8):670-83.doi:10.5551/jat.7120.

Brodeur MR, Bouvet C, Bouchard S, Moreau S, Leblond J, Deblois D, et al.Reduction of advanced-glycation end products levels and inhibition of RAGE signaling decreases rat vascular calcification induced by diabetes. PLoS One. 2014;9(1):e85922.doi:10.1371/journal.pone.0085922.

Aleksieieva N.Advantages of expanded hemodialysis (HDx) over standard hemodialysis. Ukr J Nephrol Dial. 2019;4(64):56-61. doi:10.31450/ukrjnd.4(64).2019.08.

Thomas SS, Zhang L, Mitch WE.Molecular mechanisms of insulin resistance in chronic kidney disease. Kidney Int. 2015;88(6):1233-39. doi:10.1038/ki.2015.305.

Gozhenko AI, Kuznetsova HS, Kuznetsova KS, Byts TN, Susla AB.Endothelial dysfunction in the pathogenesis of diabetes complications The message I. Endothelial dysfunction: etiology, pathogenesis and diagnostic methods. Endokrynologia. 2017;22(2):171-81.

Kikhtiak O.Insulinochutlyvi tkanyny ta markery insulinorezystentnosti za tsukrovoho diabetu 2-ho typu. Klinichna endokrynolohiia ta endokrynna khirurhiia. 2010;2:58-3. [In Ukrainian].

Cleland SJ, Petrie JR, Small M, Elliott HL, Connell JM.Insulin action is associated with endothelial function in hypertension and type 2 diabetes. Hypertension. 2000;35(1 Pt 2):507-11.doi:10.1161/01.hyp.35.1.507.

Katerenchuk I,  Zhdan V.Optymizatsiia korektsii endotelialnoi dysfunktsii u patsiientiv z metabolichnym syndromom u praktytsi simeinoho likaria. Zdobutky klinichnoi ta eksperymentalnoi medytsyny. 2014;1:39-43. [In Ukrainian].

Zhao MM, Xu MJ, Cai Y, Zhao G, Guan Y, Kong W, et al.Mitochondrial reactive oxygen species promote p65 nuclear translocation mediating high-phosphate-induced vascular calcification in vitro and in vivo. Kidney Int. 2011;79(10):1071-9.doi:10.1038/ki.2011.18.

Litovkina ZІ, Susla OB.Cardiovascular features of chronic inflammation and endothelial dysfunction in patients with diabetic nephropathy on programmed hemodialysis. Journal of Education, Health and Sport. 2020;10(10):144-57.doi:10.12775/JEHS.2020.10.10.013.

Benz K, Hilgers K-F, Daniel C, Amann K. Vascular calcification in chronic kidney disease: The role of inflammation. Int J of Nephrol. 2018;2018: Article ID 4310379.  doi:10.1155/2018/4310379.

Susla O, Litovkina Z, Mysula I,  Gozhenko A.Tumor necrosis factor alpha and magnesium are linked to cardiac valve calcification in diabetic hemodialysis patients. Nephrol Dial Transplant. 2021;36(Suppl 1):i420. doi:10.1093/ndt/gfab097.0021.

Lai J, Akindavyi G, Fu Q, Li ZL, Wang HM, Wen LH.Research Progress on the Relationship between Coronary Artery Calcification and Chronic Renal Failure. Chin Med J (Engl). 2018;131(5):608-14.doi:10.4103/0366-6999.226066.

Avci E, Cakir E, Cevher SC, Yaman H, Agilli M, Bilgi C.Determination of oxidative stress and cellular inflammation in patients with diabetic nephropathy and non-diabetic nephropathy being administered hemodialysis treatment due to chronic renal failure. Ren Fail. 2014;36(5):767-73.doi:10.3109/0886022X.2014.890841.

Rattazzi M, Bertacco E, Del Vecchio A, Puato M, Faggin E, Pauletto P. Aortic valve calcification in chronic kidney disease. Nephrol Dial Transplant. 2013;28(12):2968-76.doi:10.1093/ndt/gft310.

Neven E, De Schutter TM, Behets GJ, Gupta A, D'Haese PC.Iron and vascular calcification. Is there a link? Nephrol Dial Transplant. 2011;26(4):1137-45. doi:10.1093/ndt/gfq858.

Min HK, Sung SA, Oh YK, Kim YH, Chung W, Park SK, et al. Hepcidin, iron indices and bone mineral metabolism in non-dialysis chronic kidney disease. Nephrol Dial Transplant. 2020;35(1):147-54.doi:10.1093/ndt/gfy235.

Block GA, Pergola PE, Fishbane S, Martins JG, LeWinter RD, Uhlig K, et al.Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses. Nephrol Dial Transplant. 2019;34(7):1115-24.doi:10.1093/ndt/gfy318.

Shutov E, Kotlyarova G, Lysenko K, Ryabinskaya G, Lashutin S.The efficacy and safety of the sucroferric oxyhydxidein hemodialysis patients: results of a prospective randomized controlled trial. Nephrol Dial Transplant. 2020;35(Suppl3):iii1731.  doi:10.1093/ndt/gfaa142.P1411.

Thiem U, Soellradl I, Robl B, Watorek E, Blum S, Dumfarth A, et al.The effect of phosphate binder therapy with sucroferric oxyhydroxide on calcification propensity in chronic haemodialysis patients: a randomized, controlled, crossover trial. Clin Kidney J. 2020;14(2):631-8.doi:10.1093/ckj/sfaa154.

Ketteler M, Sprague SM, Covic AC, Rastogi A, Spinowitz B, Rakov V, et al.Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients. Nephrol Dial Transplant. 2019;34(7):1163-70.doi:10.1093/ndt/gfy127.

Sampson M, Faria N, Powell JJ, PEACH study investigators.Efficacy and safety of PT20, an iron-based phosphate binder, for the treatment of hyperphosphataemia: a randomized, double-blind, placebo-controlled, dose-ranging, Phase IIb study in patients with haemodialysis-dependent chronic kidney disease. Nephrol Dial Transplant. 2021;36(8):1399-1407. doi:10.1093/ndt/gfaa116.

Goto M, Suematsu Y, Nunes ACF, Jing W, Khazaeli M, Lau WL, et al.Ferric Citrate Attenuates Cardiac Hypertrophy and Fibrosis in a Rat Model of Chronic Kidney Disease. Iran J Kidney Dis. 2019;13(2):98-104.Available from:https://pubmed.ncbi.nlm.nih.gov/30988246/.

Ciceri P, Elli F, Braidotti P, Falleni M, Tosi D, Bulfamante G, et al.Iron citrate reduces high phosphate-induced vascular calcification by inhibiting apoptosis. Atherosclerosis. 2016;254:93-101.doi:10.1016/j.atherosclerosis.2016.09.071.

Becs G, Zarjou A, Agarwal A, Kovács KÉ, Becs Á, Nyitrai M, et al.Pharmacological induction of ferritin prevents osteoblastic transformation of smooth muscle cells. J Cell Mol Med. 2016;20(2):217-30.doi:10.1111/jcmm.12682.

Seto T, Hamada C, Tomino Y. Suppressive effects of iron overloading on vascular calcification in uremic rats. J Nephrol. 2014;27(2):135-42.doi:10.1007/s40620-014-0046-3.

Vera-Aviles M, Vantana E, Kardinasari E, Koh NL, Latunde-Dada GO.Protective Role of Histidine Supplementation Against Oxidative Stress Damage in the Management of Anemia of Chronic Kidney Disease. Pharmaceuticals (Basel). 2018;11(4):111.doi:10.3390/ph11040111.

Ciceri P, Falleni M, Tosi D, Martinelli C, CozzolinoMG.Iron citrate blocks the progression of calcium deposition by reverting apoptosis and autophagy. Nephrol Dial Transplant. 2020;35 (Suppl 3):iii1706.doi:10.1093/ndt/gfaa142.P1387.

Kétszeri M, Kirsch A, Frauscher B, Moschovaki-Filippidou F, Mooslechner AA, Kirsch AH, et al. MicroRNA-142-3p improves vascular relaxation in uremia. Atherosclerosis. 2019;280:28-36.doi:10.1016/j.atherosclerosis.2018.11.024.

Kuosmanen SM, Sihvola V, Kansanen E, Kaikkonen MU, Levonen AL.MicroRNAs mediate the senescence-associated decline of NRF2 in endothelial cells. Redox Biol. 2018;18:77-83. doi:10.1016/j.redox.2018.06.007.

Düsing P, Zietzer A, Goody PR, Hosen MR, Kurts C, Nickenig G, et al. Vascular pathologies in chronic kidney disease: pathophysiological mechanisms and novel therapeutic approaches. J Mol Med (Berl). 2021;99(3):335-348.doi:10.1007/s00109-021-02037-7.

Liu S, Zhang N.Narrative review of exosomes: novel players in vascular calcification of chronic kidney disease. Ann Palliat Med. 2021;10(12):13002-8. doi:10.21037/apm-20-910.

Wang SS, Wang C, Chen H.MicroRNAs are critical in regulating smooth muscle cell mineralization and apoptosis during vascular calcification. J Cell Mol Med. 2020;24(23):13564-72.doi:10.1111/jcmm.16005.

Staszel T, Zapała B, Polus A, Sadakierska-Chudy A, Kieć-Wilk B, Stępień E, et al.A. Role of microRNAs in endothelial cell pathophysiology. Pol Arch Med Wewn. 2011;121(10):361-6.Available from: https://pubmed.ncbi.nlm.nih.gov/21946298/.

Bellien J, Freguin-Bouilland C, Joannides R, HanoyM, Rémy-JouetI, MonteilC, et al.High-efficiency on-line haemodiafiltration improves conduit artery endothelial function compared with high-flux haemodialysis in end-stage renal disease patients. Nephrol Dial Transplant. 2014;29(2):414–22.doi:10.1093/ndt/gft448.

Susla AB, Mysula IR, Gozhenko AI. The effect of hemodialysis on endothelial dysfunction in patients with end-stage renal disease. Klin Med. 2017;95(10):935-9.doi:10.18821/0023-2149-2017-95-10-935-939.

Varan HI, Dursun B, Dursun E, OzbenT, Suleymanlar G.Acute effects of hemodialysis on oxidative stress parameters in chronic uremic patients: comparison of two dialysis membranes. Int J Nephrol Renovasc Dis. 2010;3:39-45.doi:10.2147/ijnrd.s6598.

Khaira A, Mahajan S, Kumar A, SarayaA, TiwariSC, Prakash, S, et al.Endothelial function and oxidative stress in chronic kidney disease of varying severity and effect of acute hemodialysis. Ren Fail. 2011;33(4):411-7. doi:10.3109/0886022X.2011.568138.

Seras M, de Franciscoa ÁLM, Piñera C,GundinS, García-UnzuetaM, KislikovaM, et al.Haemodialysis session: the perfect storm for vascular calcification. Nefrologia. 2015;35(5):448-56. doi:10.1016/j.nefro.2015.06.015.

Belmouaz M, Bauwens M, Hauet T, Bossard V, Jamet P, Joly F, et al.Comparison of the removal of uraemic toxins with medium cut-off and high-flux dialysers: a randomized clinical trial. Nephrol Dial Transplant. 2020;35(2):328-35.doi:10.1093/ndt/gfz189.

Cozzolino M, Magagnoli L, Ciceri P, Conte F, Galassi A.Effects of a medium cut-off (Theranova®) dialyser on haemodialysis patients: a prospective, cross-over study. Clin Kidney J. 2021;4(1):382-89. doi:10.1093/ckj/sfz155.

Zickler D, Willy K, Girndt M, Fiedler R, Martus P, Storr M, et al.High cut-off dialysis in chronic haemodialysis patients reduces serum procalcific activity. Nephrol Dial Transplant. 2016;31(10):1706-12.doi:10.1093/ndt/gfw293.

Siriopol D, Siriopol M, Stuard S, Voroneanu L, Wabel P, Moissl U, et al.An analysis of the impact of fluid overload and fluid depletion for all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2019;34(8):1385-93.doi:10.1093/ndt/gfy396.

Dekker MJ, Marcelli D, Canaud BJ, Carioni P, Wang Y, Grassmann A, MONDO Initiative.Impact of fluid status and inflammation and their interaction on survival: a study in an international hemodialysis patient cohort. Kidney Int. 2017;91(5):1214-23.doi:10.1016/j.kint.2016.12.008.

Chazot C, Deleuze S, Fadel B, Hebibi H, Jean G, Levannier M, et al.Is high-volume post-dilution haemodiafiltration associated with risk of fluid volume imbalance? A national multicentre cross-sectional cohort study. Nephrol Dial Transplant. 2019;34(12):2089-95.doi:10.1093/ndt/gfz141.

Park S, Lee CJ, Jhee JH, Yun HR, Kim H, Jung SY, et al.Extracellular Fluid Excess Is Significantly Associated With Coronary Artery Calcification in Patients With Chronic Kidney Disease. J Am Heart Assoc. 2018;7(13):e008935.doi:10.1161/JAHA.118.008935.

Mitsides N, Cornelis T, Broers NJH, Diederen NMP, Brenchley P, van der Sande FM, et al. Extracellular overhydration linked with endothelial dysfunction in the context of inflammation in haemodialysis dependent chronic kidney disease. PLoS One. 2017;12(8):e0183281.doi:10.1371/journal.pone.0183281.

von Moos S, Segerer S, Davenport A, Sadoune M, Gerritsen K, Pottecher J, et al.Vascular endothelial growth factor D is a biomarker of fluid overload in haemodialysis patients. Nephrol Dial Transplant. 2021;36(3):529-36.doi:10.1093/ndt/gfz281.


Переглядів анотації: 455
Завантажень PDF: 5220
Опубліковано
2022-11-18
Як цитувати
Susla, O., Bushtynska, O., Yakubyshyna, I., Logoyda, L., Symko, K., & Mysula, I. (2022). Потенційні механізми кардіоваскулярної кальцифікації у хворих на хронічну хворобу нирок. Український Журнал Нефрології та Діалізу, (4(76), 69-80. https://doi.org/10.31450/ukrjnd.4(76).2022.09
Номер
№ 4(76) (2022): Ukrainian Journal of Nephrology and Dialysis
Розділ
Школа нефролога
Creative Commons License

Ця робота ліцензується відповідно до Creative Commons Attribution 4.0 International License.